Symbols / ACAD
ACAD Chart
About
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.22B |
| Enterprise Value | 3.44B | Income | 261.17M | Sales | 1.05B |
| Book/sh | 5.42 | Cash/sh | 5.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 653 | IPO | — |
| P/E | 16.11 | Forward P/E | 20.53 | PEG | — |
| P/S | 4.03 | P/B | 4.60 | P/C | — |
| EV/EBITDA | 31.72 | EV/Sales | 3.29 | Quick Ratio | 2.77 |
| Current Ratio | 3.02 | Debt/Eq | 5.97 | LT Debt/Eq | — |
| EPS (ttm) | 1.55 | EPS next Y | 1.22 | EPS Growth | 112.80% |
| Revenue Growth | 11.30% | Earnings | 2026-02-25 | ROA | 5.11% |
| ROE | 34.95% | ROIC | — | Gross Margin | 59.00% |
| Oper. Margin | 12.83% | Profit Margin | 24.94% | Shs Outstand | 169.18M |
| Shs Float | 125.35M | Short Float | 8.62% | Short Ratio | 7.56 |
| Short Interest | — | 52W High | 28.35 | 52W Low | 13.40 |
| Beta | 0.66 | Avg Volume | 1.39M | Volume | 1.76M |
| Target Price | $31.60 | Recom | Buy | Prev Close | $24.59 |
| Price | $24.97 | Change | 1.55% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$31.60
Mean price target
2. Current target
$24.97
Latest analyst target
3. DCF / Fair value
$2.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$24.97
Low
$17.00
High
$40.00
Mean
$31.60
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | init | Wolfe Research | — → Outperform | $33 |
| 2026-02-23 | up | Mizuho | Neutral → Outperform | $35 |
| 2026-02-06 | main | Oppenheimer | Perform → Perform | $23 |
| 2026-02-03 | main | RBC Capital | Outperform → Outperform | $31 |
| 2026-02-03 | reit | Citizens | Market Outperform → Market Outperform | $34 |
| 2026-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $37 |
| 2026-01-06 | main | Citigroup | Buy → Buy | $36 |
| 2026-01-06 | main | UBS | Buy → Buy | $40 |
| 2025-12-15 | main | HC Wainwright & Co. | Buy → Buy | $37 |
| 2025-12-11 | main | Stifel | Hold → Hold | $25 |
| 2025-12-02 | main | Mizuho | Neutral → Neutral | $29 |
| 2025-11-17 | main | JP Morgan | Overweight → Overweight | $31 |
| 2025-11-06 | main | RBC Capital | Outperform → Outperform | $32 |
| 2025-11-06 | main | Needham | Buy → Buy | $29 |
| 2025-10-21 | init | Citigroup | — → Buy | $33 |
| 2025-09-29 | main | JP Morgan | Overweight → Overweight | $33 |
| 2025-09-24 | main | Needham | Buy → Buy | $28 |
| 2025-09-11 | main | TD Cowen | Buy → Buy | $39 |
| 2025-09-09 | main | UBS | Buy → Buy | $39 |
| 2025-08-08 | main | UBS | Buy → Buy | $36 |
- Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates - Yahoo Finance hu, 26 Feb 2026 00
- Watch Acadia’s March investor fireside chats online for a month - Stock Titan Mon, 23 Feb 2026 21
- New Analyst Forecast: $ACAD Given $35 Price Target - Quiver Quantitative Mon, 23 Feb 2026 12
- ACADIA Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat hu, 26 Feb 2026 00
- ACADIA Pharmaceuticals (ACAD) Receives New Analyst Coverage with 'Outperform' Rating | ACAD Stock News - GuruFocus ue, 24 Feb 2026 12
- Trend Report: Should you avoid ACAD stock right now - July 2025 Price Swings & Stepwise Swing Trade Plans - baoquankhu1.vn hu, 26 Feb 2026 03
- Does ACADIA (ACAD) Have the Right Pipeline Mix as It Moves Beyond Nuplazid Dependence? - simplywall.st Mon, 23 Feb 2026 21
- Why (ACAD) Price Action Is Critical for Tactical Trading - Stock Traders Daily Mon, 23 Feb 2026 01
- Wolfe Research initiates Acadia stock with outperform rating - Investing.com ue, 24 Feb 2026 15
- ACADIA (ACAD) Q4 2025 Earnings Call Transcript - The Globe and Mail Wed, 25 Feb 2026 21
- Over 1,000 Rett patients on drug as EU panel turns negative - Stock Titan Mon, 02 Feb 2026 08
- Mizuho Upgrades ACAD to Outperform, Raises Price Target Signific - GuruFocus Mon, 23 Feb 2026 14
- Is It Too Late To Consider ACADIA Pharmaceuticals (ACAD) After Its Recent Share Price Rebound? - Yahoo Finance Mon, 02 Feb 2026 08
- Insider Sale: EVP of $ACAD Sells 6,950 Shares - Quiver Quantitative ue, 10 Feb 2026 23
- ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure - Yahoo Finance hu, 25 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 6950 | 162491.0 | — | Sale at price 23.38 per share. | RHODES JENNIFER J. | Officer | — | 2026-02-09 00:00:00 | D |
| 1 | 12944 | nan | — | — | RHODES JENNIFER J. | Officer | — | 2026-02-06 00:00:00 | D |
| 2 | 10262 | 243114.0 | — | Sale at price 23.69 per share. | SCHNEYER MARK C. | Chief Financial Officer | — | 2025-11-18 00:00:00 | D |
| 3 | 4084 | 96754.0 | — | Sale at price 23.69 per share. | KIHARA JAMES | Officer | — | 2025-11-18 00:00:00 | D |
| 4 | 19826 | nan | — | — | SCHNEYER MARK C. | Chief Financial Officer | — | 2025-11-17 00:00:00 | D |
| 5 | 7932 | nan | — | — | KIHARA JAMES | Officer | — | 2025-11-17 00:00:00 | D |
| 6 | 30000 | 670983.0 | — | Sale at price 22.37 per share. | DALY JAMES M. | Director | — | 2025-11-10 00:00:00 | D |
| 7 | 3498 | 82728.0 | — | Sale at price 23.65 per share. | SCHNEYER MARK C. | Chief Financial Officer | — | 2025-09-15 00:00:00 | D |
| 8 | 6815 | — | — | Stock Award(Grant) at price 0.00 per share. | SCHNEYER MARK C. | Chief Financial Officer | — | 2025-09-12 00:00:00 | D |
| 9 | 1600 | 41560.0 | — | Sale at price 25.98 per share. | GAROFALO ELIZABETH AMY M.D. | Director | — | 2025-09-02 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 17.95M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.12 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -46.35M | -67.83M | -221.57M | -167.09M |
| TotalUnusualItems | 146.51M | 0.00 | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 146.51M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | 226.45M | -61.29M | -215.97M | -167.87M |
| ReconciledDepreciation | 15.88M | 5.55M | 2.03M | 3.34M |
| ReconciledCostOfRevenue | 81.84M | 41.64M | 10.17M | 19.14M |
| EBITDA | 100.16M | -67.83M | -221.57M | -167.09M |
| EBIT | 84.28M | -73.38M | -223.60M | -170.44M |
| NetInterestIncome | 25.46M | 17.23M | 6.61M | 591.00K |
| InterestIncome | 25.46M | 17.23M | 6.61M | 591.00K |
| NormalizedIncome | 97.89M | -61.29M | -215.97M | -167.87M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 226.45M | -61.29M | -215.97M | -167.87M |
| TotalExpenses | 873.52M | 799.82M | 740.83M | 654.58M |
| TotalOperatingIncomeAsReported | 230.79M | -73.38M | -223.60M | -170.44M |
| DilutedAverageShares | 166.36M | 163.82M | 161.68M | 160.49M |
| BasicAverageShares | 165.72M | 163.82M | 161.68M | 160.49M |
| DilutedEPS | 1.36 | -0.37 | -1.34 | -1.05 |
| BasicEPS | 1.37 | -0.37 | -1.34 | -1.05 |
| DilutedNIAvailtoComStockholders | 226.45M | -61.29M | -215.97M | -167.87M |
| NetIncomeCommonStockholders | 226.45M | -61.29M | -215.97M | -167.87M |
| NetIncome | 226.45M | -61.29M | -215.97M | -167.87M |
| NetIncomeIncludingNoncontrollingInterests | 226.45M | -61.29M | -215.97M | -167.87M |
| NetIncomeContinuousOperations | 226.45M | -61.29M | -215.97M | -167.87M |
| TaxProvision | 31.62M | 10.25M | 2.53M | 351.00K |
| PretaxIncome | 258.07M | -51.04M | -213.44M | -167.52M |
| OtherIncomeExpense | 148.34M | 5.11M | 3.54M | 2.33M |
| OtherNonOperatingIncomeExpenses | 1.82M | 5.11M | 3.54M | 2.33M |
| SpecialIncomeCharges | 146.51M | 0.00 | 0.00 | |
| GainOnSaleOfPPE | 146.51M | 0.00 | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 25.46M | 17.23M | 6.61M | 591.00K |
| InterestIncomeNonOperating | 25.46M | 17.23M | 6.61M | 591.00K |
| OperatingIncome | 84.28M | -73.38M | -223.60M | -170.44M |
| OperatingExpense | 791.68M | 758.18M | 730.66M | 635.44M |
| ResearchAndDevelopment | 303.25M | 351.62M | 361.57M | 239.41M |
| SellingGeneralAndAdministration | 488.43M | 406.56M | 369.09M | 396.03M |
| GeneralAndAdministrativeExpense | 396.03M | |||
| OtherGandA | 396.03M | |||
| GrossProfit | 875.96M | 684.80M | 507.07M | 465.00M |
| CostOfRevenue | 81.84M | 41.64M | 10.17M | 19.14M |
| TotalRevenue | 957.80M | 726.44M | 517.24M | 484.14M |
| OperatingRevenue | 957.80M | 726.44M | 517.24M | 484.14M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 166.71M | 164.65M | 162.06M | 161.01M |
| ShareIssued | 166.71M | 164.65M | 162.06M | 161.01M |
| TotalDebt | 51.99M | 57.20M | 62.00M | 64.43M |
| TangibleBookValue | 613.01M | 366.26M | 400.41M | 540.89M |
| InvestedCapital | 732.79M | 431.75M | 400.41M | 540.89M |
| WorkingCapital | 543.45M | 361.87M | 382.31M | 521.75M |
| NetTangibleAssets | 613.01M | 366.26M | 400.41M | 540.89M |
| CapitalLeaseObligations | 51.99M | 57.20M | 62.00M | 64.43M |
| CommonStockEquity | 732.79M | 431.75M | 400.41M | 540.89M |
| TotalCapitalization | 732.79M | 431.75M | 400.41M | 540.89M |
| TotalEquityGrossMinorityInterest | 732.79M | 431.75M | 400.41M | 540.89M |
| StockholdersEquity | 732.79M | 431.75M | 400.41M | 540.89M |
| GainsLossesNotAffectingRetainedEarnings | 292.00K | 24.00K | -975.00K | -192.00K |
| OtherEquityAdjustments | 292.00K | 24.00K | -975.00K | -192.00K |
| RetainedEarnings | -2.20B | -2.43B | -2.37B | -2.15B |
| AdditionalPaidInCapital | 2.94B | 2.86B | 2.77B | 2.69B |
| CapitalStock | 16.00K | 16.00K | 16.00K | 16.00K |
| CommonStock | 16.00K | 16.00K | 16.00K | 16.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 454.96M | 317.20M | 187.40M | 159.23M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 60.09M | 62.95M | 61.77M | 63.16M |
| OtherNonCurrentLiabilities | 18.06M | 15.15M | 9.07M | 7.03M |
| LongTermDebtAndCapitalLeaseObligation | 42.04M | 47.80M | 52.70M | 56.13M |
| LongTermCapitalLeaseObligation | 42.04M | 47.80M | 52.70M | 56.13M |
| CurrentLiabilities | 394.87M | 254.25M | 125.63M | 96.07M |
| CurrentDebtAndCapitalLeaseObligation | 9.96M | 9.40M | 9.30M | 8.30M |
| CurrentCapitalLeaseObligation | 9.96M | 9.40M | 9.30M | 8.30M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 36.55M | 42.72M | 28.02M | 25.90M |
| PayablesAndAccruedExpenses | 348.36M | 202.13M | 88.30M | 61.87M |
| CurrentAccruedExpenses | 320.15M | 183.02M | 75.18M | 54.99M |
| Payables | 28.21M | 19.11M | 13.12M | 6.88M |
| TotalTaxPayable | 12.02M | 1.56M | 377.00K | |
| AccountsPayable | 16.19M | 17.54M | 12.75M | 6.88M |
| TotalAssets | 1.19B | 748.96M | 587.81M | 700.12M |
| TotalNonCurrentAssets | 249.44M | 132.83M | 79.88M | 82.30M |
| OtherNonCurrentAssets | 78.87M | 10.87M | 18.28M | 15.98M |
| GoodwillAndOtherIntangibleAssets | 119.78M | 65.49M | 0.00 | 0.00 |
| NetPPE | 50.79M | 56.47M | 61.59M | 66.31M |
| AccumulatedDepreciation | -10.22M | -9.56M | -8.10M | -6.18M |
| GrossPPE | 61.00M | 66.02M | 69.69M | 72.50M |
| Leases | 3.75M | 3.75M | 3.70M | 3.70M |
| ConstructionInProgress | 523.00K | 0.00 | ||
| OtherProperties | 46.57M | 51.85M | 55.57M | 58.27M |
| MachineryFurnitureEquipment | 10.16M | 10.42M | 10.42M | 10.54M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 938.32M | 616.12M | 507.94M | 617.82M |
| PrepaidAssets | 55.68M | 39.09M | 21.40M | 23.89M |
| Inventory | 21.95M | 35.82M | 6.64M | 7.88M |
| FinishedGoods | 1.93M | 1.11M | ||
| WorkInProcess | 4.43M | 6.77M | ||
| RawMaterials | 283.00K | 0.00 | ||
| Receivables | 104.69M | 102.35M | 63.08M | 65.34M |
| AccruedInterestReceivable | 5.96M | 4.08M | 885.00K | 978.00K |
| AccountsReceivable | 98.74M | 98.27M | 62.20M | 64.37M |
| CashCashEquivalentsAndShortTermInvestments | 755.99M | 438.87M | 416.82M | 520.71M |
| OtherShortTermInvestments | 436.40M | 250.21M | 301.98M | 373.27M |
| CashAndCashEquivalents | 319.59M | 188.66M | 114.85M | 147.44M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 157.20M | -23.35M | -114.03M | -126.78M |
| IssuanceOfCapitalStock | 6.84M | 25.13M | 8.20M | 18.16M |
| CapitalExpenditure | -523.00K | -40.05M | -1.12M | |
| IncomeTaxPaidSupplementalData | 19.52M | 5.85M | 2.19M | 1.04M |
| EndCashPosition | 328.36M | 194.43M | 120.62M | 153.21M |
| BeginningCashPosition | 194.43M | 120.62M | 153.21M | 331.80M |
| EffectOfExchangeRateChanges | -94.00K | -18.00K | 6.00K | 7.00K |
| ChangesInCash | 134.03M | 73.83M | -32.59M | -178.60M |
| FinancingCashFlow | 6.84M | 25.13M | 8.20M | 18.16M |
| CashFlowFromContinuingFinancingActivities | 6.84M | 25.13M | 8.20M | 18.16M |
| NetCommonStockIssuance | 6.84M | 25.13M | 8.20M | 18.16M |
| CommonStockIssuance | 6.84M | 25.13M | 8.20M | 18.16M |
| InvestingCashFlow | -30.54M | 32.00M | 73.24M | -71.10M |
| CashFlowFromContinuingInvestingActivities | -30.54M | 32.00M | 73.24M | -71.10M |
| NetOtherInvestingChanges | 146.51M | |||
| NetInvestmentPurchaseAndSale | -176.53M | 72.05M | 73.24M | -69.98M |
| SaleOfInvestment | 328.56M | 442.03M | 436.42M | 422.82M |
| PurchaseOfInvestment | -505.10M | -369.99M | -363.17M | -492.80M |
| NetIntangiblesPurchaseAndSale | 0.00 | -40.00M | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | -523.00K | -50.00K | 0.00 | -1.12M |
| PurchaseOfPPE | -523.00K | -50.00K | 0.00 | -1.12M |
| OperatingCashFlow | 157.72M | 16.70M | -114.03M | -125.66M |
| CashFlowFromContinuingOperatingActivities | 157.72M | 16.70M | -114.03M | -125.66M |
| ChangeInWorkingCapital | 4.16M | 18.13M | 37.99M | -24.82M |
| ChangeInOtherCurrentLiabilities | -4.69M | 201.00K | -5.88M | -3.58M |
| ChangeInOtherCurrentAssets | 7.62M | 5.74M | 6.52M | 6.30M |
| ChangeInPayablesAndAccruedExpense | 69.71M | 97.97M | 30.18M | -10.07M |
| ChangeInAccruedExpense | 71.06M | 93.17M | 24.31M | -8.46M |
| ChangeInPayable | -1.35M | 4.80M | 5.87M | -1.62M |
| ChangeInAccountPayable | -1.35M | 4.80M | 5.87M | -1.62M |
| ChangeInPrepaidAssets | -16.59M | -17.69M | 2.49M | 1.80M |
| ChangeInInventory | -49.55M | -28.81M | 2.42M | -4.21M |
| ChangeInReceivables | -2.35M | -39.27M | 2.26M | -15.06M |
| ChangesInAccountReceivables | -472.00K | -36.07M | 2.17M | -16.12M |
| StockBasedCompensation | 67.05M | 66.42M | 68.20M | 63.62M |
| AmortizationOfSecurities | -9.30M | -7.53M | -2.74M | 2.40M |
| DepreciationAmortizationDepletion | 15.88M | 5.55M | 2.03M | 3.34M |
| DepreciationAndAmortization | 15.88M | 5.55M | 2.03M | 3.34M |
| AmortizationCashFlow | 14.96M | 4.09M | 0.00 | 1.11M |
| AmortizationOfIntangibles | 14.96M | 4.09M | 0.00 | 1.11M |
| Depreciation | 920.00K | 1.46M | 2.03M | 2.24M |
| OperatingGainsLosses | -146.51M | -4.58M | -3.54M | -2.33M |
| GainLossOnInvestmentSecurities | -4.58M | -3.54M | -2.33M | |
| NetIncomeFromContinuingOperations | 226.45M | -61.29M | -215.97M | -167.87M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ACAD
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|